Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

מידע ביבליוגרפי
Main Authors:	Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E
פורמט:	Conference item
יצא לאור:	2005

פריטים דומים

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
מאת: Pellagatti, A, et al.
יצא לאור: (2006)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
מאת: Pellagatti, A, et al.
יצא לאור: (2007)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
מאת: Jädersten, M, et al.
יצא לאור: (2009)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
מאת: Scharenberg, C, et al.
יצא לאור: (2011)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
מאת: Martin Jädersten, et al.
יצא לאור: (2009-12-01)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
מאת: Pellagatti, A, et al.
יצא לאור: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
מאת: Pellagatti, A, et al.
יצא לאור: (2011)

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion
מאת: Martin Jädersten
יצא לאור: (2010-03-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
מאת: Nikpour, M, et al.
יצא לאור: (2007)

Gene expression profiling in the myelodysplastic syndromes.
מאת: Pellagatti, A, et al.
יצא לאור: (2005)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
מאת: Raza Azra, et al.
יצא לאור: (2012-04-01)

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
מאת: Lewis, S, et al.
יצא לאור: (1995)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
מאת: Pellagatti, A, et al.
יצא לאור: (2009)

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
מאת: Maria Ximeri, et al.
יצא לאור: (2010-03-01)

The impact of spliceosome mutations in MDS
מאת: Jacqueline Boultwood, et al.
יצא לאור: (2019-06-01)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
מאת: Pellagatti, A, et al.
יצא לאור: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
מאת: Pellagatti, A, et al.
יצא לאור: (2010)

5q- syndrome.
מאת: Boultwood, J, et al.
יצא לאור: (2012)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
מאת: Pellagatti, A, et al.
יצא לאור: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
מאת: Pellagatti, A, et al.
יצא לאור: (2010)

Clonality in the myelodysplastic syndromes.
מאת: Boultwood, J, et al.
יצא לאור: (2001)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
מאת: Caceres, G, et al.
יצא לאור: (2013)

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
מאת: Gudrun Göhring, et al.
יצא לאור: (2011-02-01)

The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
מאת: Nilsson, L, et al.
יצא לאור: (2007)

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
מאת: Axel Rüfer, et al.
יצא לאור: (2022-07-01)

Molecular pathogenesis of the myelodysplastic syndromes
מאת: Boultwood, J, et al.
יצא לאור: (1999)

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
מאת: Virginie Eclache, et al.
יצא לאור: (2008-02-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
מאת: Pellagatti, A, et al.
יצא לאור: (2003)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
מאת: Pellagatti, A, et al.
יצא לאור: (2009)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
מאת: Botezatu, L, et al.
יצא לאור: (2016)

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide
מאת: Bagi Jana, et al.
יצא לאור: (2014-01-01)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
מאת: Pellagatti, A, et al.
יצא לאור: (2005)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
מאת: Boultwood, J, et al.
יצא לאור: (2012)

Telomere length in myelodysplastic syndromes.
מאת: Boultwood, J, et al.
יצא לאור: (1995)

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
מאת: Pellagati, A, et al.
יצא לאור: (2008)

Advances in the 5q- syndrome.
מאת: Boultwood, J, et al.
יצא לאור: (2010)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
מאת: Pellagatti, A, et al.
יצא לאור: (2004)

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells
מאת: Brigitte Mohr, et al.
יצא לאור: (2009-03-01)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
מאת: Yu Han Koh, et al.
יצא לאור: (2023-08-01)

PP2A: The Achilles Heal in MDS with 5q Deletion
מאת: David eSallman, et al.
יצא לאור: (2014-09-01)